ArticlePharmacoEconomics - open2023

Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada.

Reka E Pataky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.